---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011106"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:39:33.746231+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY

## Summary
- Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.
- Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).
- Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.
- Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026.

## SEC filing metadata
- accession: 0001193125-26-011106
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/0001193125-26-011106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011106
- JSON: https://secwatch.observer/filing/0001193125-26-011106.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.